List view / Grid view
28 September 2015 | By Victoria White
Median progression-free survival was 5.4 months on the ramucirumab-docetaxel arm as compared to 2.8 months for patients treated with docetaxel alone...
28 September 2015 | By Victoria White
While VS-6063 had a generally well tolerated safety profile, there was not a sufficient level of efficacy to warrant continuation of the study...
28 September 2015 | By Victoria White
Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy...
28 September 2015 | By Victoria White
The combination also demonstrated significant health-related quality of life improvements, including overall health, physical and social functioning...
28 September 2015 | By Victoria White
The approval provides a new interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan...
25 September 2015 | By Victoria White
The CHMP’s recommendation is based primarily on results of a Phase III study that showed that people who received the combination of Cotellic and Zelboraf lived over a year without their disease worsening...
25 September 2015 | By Victoria White
The CHMP’s recommendation will now be reviewed by the European Commission. If approved, Genvoya would be Gilead’s first single tablet regimen to contain TAF...
25 September 2015 | By Victoria White
Idarucizumab is intended for use in patients treated with dabigatran who require immediate anticoagulant reversal prior to urgent procedures or in case of uncontrolled bleeding...
25 September 2015 | By Victoria White
Elocta is a recombinant factor VIII Fc fusion protein product that, if approved, would be the first haemophilia A treatment with prolonged circulation available in the EU...
25 September 2015 | By Victoria White
The trial investigated the efficacy and safety of semaglutide compared with exenatide in 813 people with type 2 diabetes...
25 September 2015 | By Victoria White
The CHMP adopted a positive opinion for an expanded indication of azacitidine for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia who are not eligible for haematopoietic stem cell transplantation...
25 September 2015 | By Victoria White
The CHMP has adopted a positive opinion for Novartis’ Entresto (sacubitril/valsartan), marking an important milestone towards the drug becoming available in the EU.
25 September 2015 | By Victoria White
The British Generic Manufacturers Association, the Association of the British Pharmaceutical Industry (ABPI), and the UK BioIndustry Association (BIA) have joined forces to welcome NHS England’s new publication “What is a biosimilar medicine?”.
The official opening ceremony was performed by Mr Hiromitsu Kuramoto, President of Yusen Logistics. Mr. Kuramoto joined with Yusen Logistics colleagues in welcoming guests including customers, Airport officials and Customs authorities at the inauguration event.
24 September 2015 | By Victoria White
Mepolizumab is an anti-IL 5 monoclonal antibody that is delivered in a 100mg dose via subcutaneous injection every four weeks...
